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ABSTRACT
Several studies have indicated an important role for miR-155 in the pathogenesis 
of B-cell lymphoma. Highly elevated levels of miR-155 were indeed observed in 
most B-cell lymphomas with the exception of Burkitt lymphoma (BL). However, the 
molecular mechanisms that underlie the oncogenic role of miR-155 in B-cell lymphoma 
are not well understood. To identify the miR-155 targets relevant for B-cell lymphoma, 
we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) 
cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155. 
We identified 54 miR-155-specific target genes in BL cells and confirmed miR-155 
targeting of DET1, NIAM, TRIM32, HOMEZ, PSIP1 and JARID2. Five of these targets 
are also regulated by endogenous miR-155 in HL cells. Both overexpression of miR-
155 and inhibition of expression of the novel miR-155 target gene NIAM increased 
proliferation of BL cells. In primary B-cell lymphoma NIAM-positive cases have 
significant lower levels of miR-155 as compared to NIAM-negative cases, suggesting 
that NIAM is also regulated by miR-155 in primary B-cell lymphoma. Thus, our data 
indicate an oncogenic role for miR-155 in B-cell lymphoma which involves targeting 
the tumor suppressor NIAM.
INTRODUCTION 
MiRNAs are short (21-23 nucleotides) non-coding 
RNA molecules that mediate posttranscriptional silencing 
of their target genes [1]. MiRNA-dependent expression 
regulation is crucial in cellular processes including cell 
cycle, apoptosis and proliferation. Deregulated miRNA 
levels have been observed in various hematological 
malignancies, including B-cell lymphomas [2]. 
MiR-155 is one of the most frequently studied 
miRNAs in normal and malignant B-cells. Studies in 
mice revealed an important regulatory role of miR-155 in 
diverse aspects of the immune response including B-cell 
development. Most germinal center (GC) B cells express 
the primary transcript of miR-155, BIC / MIR155HG, and 
harbor high levels of the mature miR-155 in the course 
of the GC response [3]. Several studies implicate an 
important role for miR-155 in the pathogenesis of B-cell 
leukemia and lymphoma. Overexpression of miR-155 
driven by the B-cell-specific Eµ-enhancer induced pre-
B-cell lymphoma in miR-155 transgenic mice [4]. In a 
similar study induction of miR-155 in murine lymphoid 
tissues caused a clonal, transplantable pre-B-cell 
malignancy that was dependent on miR-155 expression 
[5]. In human, high miR-155 levels were observed in 
GC B cell-derived lymphomas like Hodgkin lymphoma 
(HL), chronic lymphocytic leukemia, primary mediastinal 
B-cell lymphoma and diffuse large B-cell lymphoma [6-
8]. In contrast, Burkitt lymphoma (BL) is characterized 
by very low miR-155 levels [9]. Over the past few years 
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several miR-155 target genes involved in functioning of 
normal hematopoietic cells have been identified [10-12]. 
However, it is largely unknown which target genes are 
involved in the pathogenesis of B-cell lymphoma.
To identify miR-155 target genes relevant for the 
pathogenesis of B-cell lymphoma we performed Ago2-
immunoprecipitation in B-cell lymphomas with high 
and low miR-155 expression levels. Next, we tested 
which of the identified targets were involved in the 
oncogenic effect of miR-155 overexpression and showed 
that downregulation of NIAM reproduced the enhanced 
growth phenotype of miR-155 overexpression. Finally, we 
show that miR-155 levels are in general high in NIAM-
negative B-cell lymphomas and vice versa, supporting a 
role for miR-155 mediated downregulation of NIAM in 
the pathogenesis of B-cell lymphoma.
RESULTS
Unbiased genome-wide identification of miR-155 
target genes in B-cell lymphoma
To determine the target genes of miR-155 in B-cell 
lymphoma we performed Ago2-RIP-Chip following two 
strategies. On one hand we stably overexpressed miR-155 
in a BL cell line (ST486) known to have low miR-155 
levels. On the other hand we inhibited miR-155 with a 
miRNA-155 sponge construct in 2 HL cell lines (KM-H2 
and L1236), both known to have high miR-155 levels. 
Overexpression of miR-155 in ST486 cells was confirmed 
by qRT-PCR and revealed a ~500 fold increase in miR-155 
levels (Suppl. Fig. S1A). These levels are comparable to 
the endogenous miR-155 levels observed in HL cell lines 
KM-H2 and L1236. Efficiency of the IP procedure was 
confirmed by Western blot and miRNA qRT-PCR (Suppl. 
Fig. S1B-S1D). 
We defined the miRNA targetome as all transcripts 
that were ≥ 2-fold enriched in the immunoprecipitated 
(IP) fraction compared to the total (T) fraction (IP fold 
enrichment, IP/T ratio ≥ 2). The number of Ago2-IP-
enriched probes was similar in all three cell lines, ranging 
between 12.5%-17.7% of the consistently-expressed 
probes (Suppl. Table S1). To identify the miR-155-specific 
targets in ST486 cells we determined which probes had 
an IP/T ratio of ≥ 2-fold in miR-155-transduced cells 
and showed an at least 2-fold lower IP/T ratio in EV-
transduced cells. In total 64 probes (3.5% of all IP 
enriched probes) detecting 54 different genes fulfilled 
these criteria (3 probes did not correspond to any known 
gene, Suppl. Table S2). Similar analyses were performed 
for the two HL cell lines, i.e. probes with a ≥ 2-fold IP 
enrichment in EV-transduced cells and an at least 2-fold 
lower IP enrichment in miR-155 sponge-transduced cells. 
This revealed only 19 (0.5% of all IP probes) and 6 (0.3% 
of all IP probes) probes that fulfill these criteria in KM-H2 
and L1236 cells, respectively (data not shown).
Next, we performed gene set enrichment analysis 
(GSEA) to determine whether specific gene sets were 
enriched in the IP fractions. We noted that 40-75% of 
the 20 most enriched gene sets corresponded to miRNA 
binding site motif gene sets, indicating an efficient 
enrichment of miRNA target genes in all IP fractions. As 
a result of the overexpression of miR-155 in ST486 cells, 
the rank of the miR-155-binding site motif gene set was 
increased from 46th in EV-ST486 to 13th in miR-155-ST486 
cells (Fig. 1A) (Suppl. Table S3). In HL cells, the EV-
transduced lines already showed clear enrichment of miR-
155 target genes in the IP fraction (Fig. 1A). However, 
the ranking of the miR-155-binding site motif set did 
not decrease clearly in KM-H2 (rank 25th to rank 24th) or 
L1236 (rank 8th to rank 9th) cells upon overexpression of 
the miR-155 sponge (Suppl. Tables S4, S5). Thus, GSEA 
shows that in ST486 cells miR-155 targets are enriched 
in the Ago2-IP fraction upon miR-155 overexpression, 
whereas HL cells do not show a clear depletion of miR-
155 targets upon miR-155 inhibition. The GSEA results 
for the HL cell lines, as well as the more limited number 
of putative specific miR-155 targets, suggested that the 
miR-155 sponge did not effectively sequester all miR-155 
molecules, probably because of the very high endogenous 
miR-155 expression levels in KM-H2 and L1236 cells 
(Fig. S1A). 
Analysis of the IP/T ratios of the 54 ST486 miR-155 
target genes in the HL cell lines, revealed enrichment for 
45 out of 53 (85%) and 25 out of 43 (58%) target genes 
in EV-transduced L1236 and KM-H2 cells respectively, 
indicating that these targets are regulated by one or 
more miRNAs in the wild type HL cell lines (Suppl. 
Fig. S2). The other ST486 miR-155 targets were either 
not expressed in L1236 and KM-H2 cells (1 and 11), 
more mildly enriched (1.5 ≤ IP/T ≤ 2 for 3 and 10) or not 
enriched (IP/T ≤ 1.5 for 5 and 8). 
The enrichment of miR-155 targets in miR-155-
ST486 compared to EV-ST486 cells ranged from 2.0 to 
12.6 fold (Fig. 1B). In silico validation indicated that 26 
out of 54 genes (48%) contained an 8-mer (AGCATTAA) 
and 43 genes (80%) a 6-mer (GCATTA) miR-155 binding 
site in their 3’UTRs (Suppl. Table S2). Moreover, 33% 
(18 out of 54) of the identified genes were predicted to be 
miR-155 targets by TargetScan [13]. This is a significant 
increase as compared to the 1.7% predicted miR-155 
targets among all expressed genes (p < 0.0001, Chi-
square test). Thus, we identified 54 miR-155 target genes 
by overexpression of miR-155 of which the vast majority 
was also targeted by miRNAs in B-cell lymphoma cell 
lines with high endogenous levels of miR-155.
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Validation of miR-155 target genes
We selected six genes identified by Ago2-RIP-
Chip in ST486 cells for validation, i.e. one known miR-
155 target gene, Jumonji AT rich interactive domain 2 
(JARID2), and the five genes with the highest Ago2-IP 
Figure 1: Identification of miR-155 target genes using Ago2-immunoprecipitation. A. Gene set enrichment plot of the miR-
155-binding site motif comparing the Ago2-IP fraction to the total fraction shows strong enrichment of miR-155 target genes in the IP 
fractions of miR-155-ST486, EV-L1236 and EV-KM-H2 cells. B. Overview of the 54 genes that were enriched more prominently in the 
Ago2-IP fraction of miR-155-ST486 cells compared to that of EV-ST486 cells. The names of the 6 genes selected for further analysis are 
indicated. Grey bars indicate genes that are predicted miR-155 targets according to TargetScan. The dashed line indicates the cutoff of 
2-fold higher enrichment in the Ago2-IP fraction of miR-155-ST486 compared to EV-ST486 cells. The total list of genes is shown in Table 
S2. C. Five of the six selected genes are also enriched in the Ago2-IP fraction of HL cells. Shown are the IP/T (immunoprecipitated fraction/
total fraction) ratios of the six selected miR-155 target genes. Five of these genes, DET1, NIAM, HOMEZ, PSIP1 and JARID2 also show 
IP/T>2 in EV-L1236 and EV-KM-H2 cells. TRIM32 is not expressed in L1236 and 1.75 fold enriched in EV-KM-H2 cells. D. Schematic 
overview of 3’UTR or CDS (HOMEZ) regions with the positions of the predicted miR-155 binding sites indicated by the arrows (6-mer 
and 8-mer sites). For NIAM and PSIP1, the 3’UTR of the isoforms containing the miR-155 binding sites are shown (ENST00000441174 
and NM_021144, respectively). E. All 6 selected genes, but not the EV control, are targeted by miR-155 in luciferase reporter assay. For 
each construct, the Renilla/Firefly luciferase (RL/FL) ratio upon co-transfection with the miR-155 precursor is shown relative to a negative 
control co-transfection that was set to 100%. P-values were calculated with an unpaired t-test (* p < 0.05, ** p < 0.01, *** p < 0.001). F. 
DET1 protein level was decreased in miR-155-ST486 compared to EV-ST486 cells. Western blot for DET1 relative to GAPDH, EV-ST486 
was set as 1, the average of 2 experiments is shown. 
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enrichment upon miR-155 overexpression (>4-fold, 
Fig. 1B, Suppl. Table S2), i.e. De-Etiolated-1 homolog 
(DET1), Nuclear Interactor of ARF and Mdm2 (NIAM, 
the protein-coding transcript splice variant of the TBRG1 
locus), Tripartite motif-32 (TRIM32), Homeobox leucine 
zipper (HOMEZ) and PC4 and SFRS1 interacting protein 
1 (PSIP1). We confirmed Ago2-IP enrichment in the HL 
EV-transduced cells for 5 of the 6 targets (Fig. 1C). The 
6th gene, i.e. TRIM32, was not expressed in L1236 and was 
borderline enriched in KM-H2 cells (IP/T ratio = 1.75). 
For 4 out of the 5 miR-155 targets the IP enrichment was 
mildly decreased upon miR-155-sponge overexpression in 
L1236 and for 5 out of 6 in KM-H2 cells. This suggests 
that these genes are also targeted by endogenously 
expressed miR-155 in HL cells (Suppl. Fig. S2). To 
validate a direct interaction between miR-155 and these 
targets we cloned their predicted miR-155 binding sites 
into the psiCHECK2 luciferase vector. For DET1, NIAM, 
TRIM32, PSIP1 and JARID2 these sites were located 
in their 3’UTRs and for HOMEZ they were predicted 
in the coding sequence (Fig. 1D). For all 6 genes, co-
transfection of the resulting luciferase constructs with a 
miR-155 precursor into ST486 wild-type cells resulted in 
significantly decreased relative luciferase levels (range 
15-53%) compared to co-transfection with a negative 
control precursor (Fig. 1E). In addition, the highest Ago2-
IP-enriched gene upon miR-155 overexpression in ST486 
cells, i.e. DET1, showed a decreased protein level upon 
miR-155 induction in ST486 cells (Fig. 1F). Thus, we 
confirmed that DET1, NIAM, TRIM32, HOMEZ, PSIP1 
and JARID2 are valid miR-155 target genes. 
Both miR-155 overexpression and inhibition of 
miR-155 target NIAM result in enhanced cell 
growth 
In line with an oncogenic role in B-cell lymphoma, 
overexpression of miR-155 in ST486 cells caused 
accelerated growth, resulting in ~2-fold increase in the 
percentage of GFP+ cells in 22 days (Fig. 2A). Consistent 
with the mild effects of the miR-155 sponge in the Ago2-
IP experiments, no clear effects on cell growth were 
observed upon overexpression of the miR-155 sponge in 
HL cell lines L1236 and KM-H2 (data not shown). 
To determine whether inhibition of any of the 6 
validated miR-155 target genes could reproduce the miR-
155 overexpression phenotype we generated two shRNA 
constructs per gene. For 5 of the 6 targets at least one of 
the 2 shRNAs showed a 50% reduction at the protein 
or RNA level (Suppl. Fig. S3A and S3B). For HOMEZ 
both shRNAs were not effective (data not shown). GFP 
competition assays using all shRNAs revealed that 
for only one of the miR-155 target genes, i.e. NIAM, 
an increased cell growth was observed.  Inhibition of 
NIAM using NIAMsh1 but not NIAMsh2 increased the 
number of GFP+ cells by ~50%, approximately half of the 
effect of miR-155 overexpression (Fig. 2B). To explain 
the discrepancy between the two NIAM shRNAs, we 
studied the expression pattern of TBRG1 splice variants. 
Published RNA-seq data in BL cell line Mutu1 revealed 
that two isoforms were most abundant, i.e. isoform 
ENST000004411740 (the protein-coding transcript variant 
known as NIAM which contains a miR-155-binding site) 
and ENST00000473629 (non-coding TBRG1 transcript 
with no miR-155-binding site) (Fig. 2C) [14]. The probe 
on our microarray that detects both isoforms (probe 
1) showed signals ~8 times higher than the probe that 
specifically detects the miR-155-binding site containing 
NIAM transcript (probe 2) (Fig. 2D). However, only the 
latter probe detecting the NIAM transcript was enriched in 
the IP fraction (Fig. 2E). NIAMsh1, that phenocopied the 
miR-155 overexpression effect, was directed against the 
NIAM transcript and not the non-coding TBRG1 transcript 
(Fig. 2C). This resulted in >60% downregulation of the 
NIAM transcript while the total TBRG1 transcript levels 
were not affected (Fig. 2F and 2G).  NIAMsh2, which was 
directed against both isoforms of the TBRG1 locus, did not 
show any effect in the GFP competition assay. In line with 
this, NIAMsh2 did not affect NIAM transcript levels (data 
not shown) possibly due to the much higher abundance of 
the non-protein-coding transcript. Despite several attempts 
we were not able to design a second effective shRNA 
targeting the 137nt exon 4 that is specific to the NIAM 
transcript. Thus, NIAM inhibition phenocopied the growth 
promoting effect of miR-155 overexpression although this 
was not confirmed with a second shRNA.
NIAM expression is inversely associated with 
miR-155 levels in B-cell lymphoma
To determine whether NIAM protein expression in 
primary B-cell lymphoma is inversely associated with the 
miR-155 expression level we analyzed primary cases of 
CLL (high miR-155), DLBCL (variable miR-155) and BL 
(low miR-155) by immunohistochemistry for NIAM and 
qRT-PCR for miR-155. Two of the 14 CLL cases (14%), 
13 out of 17 (76%) DLBCL cases and all 10 BL cases 
stained positive for NIAM (Fig. 3A-3D, Suppl. Fig. S3C 
for validation of the antibody specificity). Among DLBCL, 
75% of the ABC subtype and 78% of the GCB subtype 
were NIAM-positive. MiR-155 levels were significantly 
higher in NIAM-negative as compared to NIAM-positive 
lymphoma cases (p < .0145, Mann Whitney U test, Fig. 
3E). Thus, these data support a miR-155-dependent 
regulation of NIAM protein expression in primary B-cell 
lymphoma. 
DISCUSSION 
MiR-155 is one of the most studied miRNAs in 
Oncotarget5www.impactjournals.com/oncotarget
Figure 2: Inhibition of miR-155 target NIAM phenocopies the effect of miR-155 overexpression. A. Overexpression of 
miR-155 enhanced growth of ST486 cells resulting in a ~2 fold increase in the percentage of GFP+ cells on day 22 post-transduction 
compared to day 4 (mixed model analysis, *** p < 0.001). B. The NIAM specific shRNA (NIAMsh1) that specifically inhibits the protein-
coding isoform (NIAM) of the TBRG1 locus enhanced growth of ST486 cells in the GFP competition assay (mixed model analysis, *** 
p<0.001). C. Schematic overview of the two most abundant TBRG1 isoforms. The position of the miR-155 binding site (miR-155), the 
region targeted by the shRNAs against NIAM (NIAMsh), the location of the two probes targeting transcripts of the TBRG1 locus present 
on the microarray and the qRT-PCR products specific for NIAM and total TBRG1 are indicated. D. The normalized signal intensity of probe 
1 (detecting both TBRG1 isoforms) was much higher than that of probe 2 (NIAM only) in ST486 cells. E. Probe 2 that specifically detected 
the NIAM transcript was strongly enriched in the targetome of miR-155-ST486 cells, whereas probe 1 that detected both isoforms was not 
enriched. F. QRT-PCR expression analysis confirms that NIAMsh1 can effectively target the NIAM transcript but has no impact on the 
total TBRG1 transcript level G.. The PCR products amplified in panel F and G are indicated in panel C. Expression is relative to GAPDH. 
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B-cell lymphoma. Over the past few years several miR-
155 target genes were identified, however only a few 
were shown to be relevant for the pathogenesis of B-cell 
lymphoma. In this study we identified miR-155 targets in 
B-cell lymphoma and showed that growth of BL-derived 
ST486 cells was enhanced upon overexpression of miR-
155. Phenotype copy experiments indicated that one of 
the identified miR-155 targets, i.e. NIAM, is involved 
in the miR-155-induced enhanced growth. The shRNAs 
against JARID2, PSIP1, TRIM32 and DET1 did not result 
in an enhanced cell growth indicating that these genes are 
unlikely to be involved in the enhanced growth phenotype. 
However, it might be that JARID2, PSIP1, TRIM32 
and DET1 are involved in other miR-155-dependent 
phenotypes that were not studied.
We identified 54 miR-155 target genes using Ago2-
RIP-Chip in ST486 cells with ectopic expression of miR-
155. Meier et al. performed Ago2-RIP-Seq in embryonic 
kidney HEK293 cells with ectopic miR-155 expression 
and identified 100 miR-155 target genes [15]. In good 
concordance with our study, their list included 22 of the 
54 genes we identified in ST486 cells, including DET1, 
TRIM32, HOMEZ and JARID2. These genes likely 
represent miR-155 targets common to various cell types. 
NIAM was not identified as a miR-155 target in HEK293 
cells suggesting that NIAM might be a lymphoma-specific 
target gene. 
We were not able to efficiently identify miR-155 
target genes using the miR-155-sponge approach in HL 
cells. MiR-155 sponge transcripts were expressed and 
efficiently enriched in the Ago2-IP fraction [16], yet miR-
155 target genes were only very mildly depleted in the 
Ago2-IP fraction of miR-155 sponge-transduced HL cells. 
Although miRNA-sponges can function as very potent 
miRNA targets that specifically sequester the miRNA to 
prevent it from binding to endogenous targets it is very 
well possible that sponge transcript levels in this case were 
insufficient for complete sequestering of the very highly 
expressed miR-155 [16-18].
Dorsett et al. showed that low miR-155 levels in 
normal B cells result in increased expression of the miR-
155 target gene Activation-Induced Cytidine Deaminase 
(AICDA) and this enhanced the frequency of MYC 
translocations [19]. Since MYC translocations are the 
hallmark of BL, it might be anticipated that the low miR-
155 levels observed in BL are especially crucial at the 
initiation step of the malignant transformation of germinal 
center B cells. A recent follow-up study showed that 
mature B cells isolated from miR-155 deficient mice have 
higher p53 activity [20]. This was shown to be mediated 
in part by AICDA and in part by the miR-155 target 
SOCS1. In BL, the putative undesired activation of p53 
via increased expression of the miR-155 target SOCS1 
needs to be blocked by direct or indirect inactivation 
of p53. In line with the proposed oncogenic role of 
miR-155, in this study we showed that ectopic miR-
155 overexpression enhances the growth of BL cell line 
ST486. However, miR-155 most likely does not function 
as an oncogene in the pathogenesis of BL, since miR-155 
levels in general are low in BL. This is in contrast to other 
subtypes of B-cell lymphoma that have strongly increased 
levels of miR-155 and do not depend on AICDA-driven 
Figure 3: Inverse correlation between NIAM protein expression and miR-155 levels in primary cases of B-cell 
lymphoma. Sections from B-cell lymphoma cases with various levels of miR-155 were stained with anti-NIAM antibody. A. BL case 
positive for NIAM. B. CLL case negative for NIAM. C. A NIAM-positive and D. NIAM-negative DLBCL case. Representative images 
are shown. Image magnifications 400x. E. Significant differences in miR-155 levels were observed between primary B-cell lymphoma 
cases with or without NIAM protein expression (Mann Whitney U test, * p < 0.05). MiR-155 levels were determined by qRT-PCR and 
normalized to RNU49 levels.
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MYC translocations, but may benefit from the miR-155-
mediated suppression of SOCS1 resulting in reduced p53 
activity [6-8].
Inhibition of NIAM expression recapitulated, at 
least in part, the growth promoting phenotype induced 
by miR-155 overexpression in ST486 cells. We were 
not able to quantify the endogenous NIAM levels by 
Western blotting using the commercial NIAM antibody 
or a published NIAM antibody [21]. It should be noted 
that cellular NIAM levels are maintained at relative low 
levels due to Mdm2-dependent ubiquitination [22]. The 
inability to detect the endogenous NIAM also prevented a 
comparison between NIAM protein levels upon miR-155 
overexpression and upon shRNA-based NIAM inhibition. 
Thus, we could not determine whether differences in the 
effects of miR-155 overexpression and NIAM knockdown 
are caused by differences in NIAM protein levels or due to 
other genes simultaneously targeted by miR-155. 
We showed that NIAM protein expression 
inversely correlated with miR-155 levels in primary 
B-cell lymphoma. NIAM staining was predominantly 
cytoplasmic. This is in contrast to the results reported by 
Reed et al., who showed that NIAM is localized in the 
nucleus and bound to chromatin [23]. Nonetheless and 
similar to our study, NIAM was clearly localized in the 
cytoplasm of 2 pancreatic cell lines [21]. These different 
staining patterns indicate that NIAM can be both nuclear 
and cytoplasmic. Microarray studies indicated that NIAM 
transcript levels are lowered in various types of cancer, 
including B-cell lymphoma [22]. The tumor suppressive 
function of NIAM was confirmed in a recent study that 
showed that NIAM-deficient mice were predisposed 
to develop proliferative lesions, including early stage 
B-cell lymphoma [24]. Moreover, NIAM was shown 
to act as a tumor suppressor protein linked to the p53 
pathway in several ways [22, 23]. It stimulated p53 
activity by interacting with p53 regulators such as Mdm2 
and Tip60 [23]. Exogenous NIAM stabilized p53 by 
binding to Mdm2 and preventing Mdm2-mediated p53 
ubiquitylation, and association of NIAM with Tip60 
increased p53 transactivation of the p21 promoter. In 
addition, exogenous NIAM was shown to inhibit cell 
proliferation independent of p53 [25]. It would be 
interesting to study whether the NIAM-mediated effect of 
miR-155 depends on decreased p53 activity.
In conclusion, we identified NIAM as a novel miR-
155 target gene in B-cell lymphoma. Induction of miR-
155 enhances growth of ST486 BL cells and our data 
indicate that this is at least in part caused by inhibition 
of NIAM. NIAM expression inversely correlated with 
miR-155 levels in primary B-cell lymphoma. Our data, 
together with the recent observation that NIAM-deficient 
mice are predisposed to malignant transformation suggest 
that NIAM is a crucial target for the oncogenic effects of 
miR-155 in B-cell lymphoma. 
MATERIALS AND METHODS 
Tissue samples
Individual diagnosis of the 10 BL, 14 CLL and 
17 DLBCL samples were reviewed by an experienced 
hematopathologist for consistent morphology and 
immunophenotype according to the 2008 WHO 
classification [26]. Pediatric BL cases presented with an 
abdominal mass and were CD10+, BCL2- and MYC-
breakpoint+. CLL cases were nodal and CD5+, CD23+, 
cyclinD1- with variable ZAP70 expression. Diffuse large 
B-cell lymphoma (DLBCL) cases were classified into 
ABC (8) or GCB (9) subtypes according to the Hans 
algorithm [27]. All protocols for obtaining human tissue 
samples were performed in accordance to the guidelines 
from the Institutional review board or Medical Ethical 
committee of the University Medical Center Groningen.
Cell lines
ST486, L1236 and KM-H2 cell lines were 
cultured as previously described [28, 29]. Cell lines were 
purchased from ATCC (ST486) or DSMZ (L1236 and 
KM-H2). Phoenix-ampho cells were cultured in DMEM 
supplemented with 10% fetal calf serum. 
DNA constructs and viral transductions
To overexpress miRNA-155, the pre-miRNA with 
flanking sequences was amplified from genomic DNA 
using primers listed in Table S6. Insert was cloned into 
the retroviral MXW-PGK-IRES-GFP vector [30] using 
XhoI and EcoRI. To validate miRNA overexpression, 
GFP+ cells were sorted ~2 weeks after transduction using 
a MoFlo sorter (Dako cytomation). We inhibited miR-
155 using a retrovirally expressed miR-155 sponge with 
14 binding sites (Table S6) [16]. The 3’UTR of DET1, 
TRIM32, JARID2, PSIP1, NIAM and the ~300nt coding 
sequence fragment of HOMEZ containing the potential 
miR-155-binding sites were amplified from genomic 
DNA using primers listed in Table S6 and cloned into the 
psiCHECK2 vector (Promega, Madison, WI). To inhibit 
miR-155 target genes, shRNA oligos were designed 
(Table S6) and cloned into the retroviral pMDH1-PGK-
GFP 2.0 vector [30]. The sequence of NIAMsh1 was based 
on a previous study [22]. Retroviral transductions were 
performed as previously described [28].
Quantitative RT-PCR
RNA isolation and miRNA-specific cDNA 
synthesis and qPCR were performed as previously 
Oncotarget8www.impactjournals.com/oncotarget
described [31, 32]. MiRNA levels were normalized to 
RNU48 or RNU49 levels. For quantification of NIAM, 
total TBRG1, DET1, TRIM32, HOMEZ, PSIP1, JARID2, 
cDNA was synthesized using random primers, dNTP mix 
and the Superscript II Reverse Transcriptase Kit (Life 
Technologies Europe BV, Bleiswijk, NL) according to 
manufacturer’s instructions. The qPCR reactions for 
NIAM and total TBRG1 were performed as previously 
described [28], GAPDH was used as a reference gene, 
primers are listed in Table S6. For DET1, TRIM32, PSIP1 
and JARID2, the qPCR reactions were performed using 
qPCR MasterMix Plus (Eurogentec, Liege, Belgium) and 
either Taqman Gene expression assays (Hs00894490_m1 
for DET1, Hs00705875_s1 for TRIM32, Hs01045711_g1 
for PSIP1 and Hs01004460_m1 for JARID2, all Applied 
Biosystems) or designed primers and probe for detection 
of HPRT as decribed previously [33]. 
Ago2-RIP-Chip procedure
Immunoprecipitation of Ago2-containing RISC 
complexes was performed as described previously [34]. 
Briefly, cleared lysates of 20-30 million cells were 
incubated with protein G Sepharose beads (GE Healthcare) 
coated with anti-Ago2 antibody (Clone 2E12-1C9, 
Abnova, Taiwan) at 4°C overnight. Anti-IgG antibody 
was used as a negative control (Millipore BV, Amsterdam, 
The Netherlands). RNA was isolated for microarray and 
qRT-PCR analysis and protein lysates were prepared 
for Western blot. Western blot for Ago2 was performed 
as described previously [34]. RNA from the total and 
Ago2-IP fractions was analyzed using 44k Human Whole 
Genome Oligo microarrays (Agilent, Santa Clara, USA). 
Labeling and hybridization were performed with 100ng of 
total RNA using the two-color Quick Amp Labeling Kit 
(ST486) or Low Input Quick Amp Labeling Kit (L1236 
and KM-H2) and Cyanine (Cy) 3 and 5 CTP Dye Packs 
according to the manufacturer’s protocol (Agilent). The 
microarray data have been deposited in NCBI’s Gene 
Expression Omnibus [35] and are accessible through GEO 
Series accession number GSE70939. Data were analyzed 
using GeneSpring GX version 12.5 (Agilent). Quantile 
normalization of the signals was performed. Probes not 
detected in more than half of the samples and that were 
inconsistent (more than 2 fold different) in Cy3 and 
Cy5 replicates of the same sample were filtered out. The 
averaged signals for Cy3 and Cy5 replicates were used to 
calculate the IP/T ratio for each sample.
Gene Set Enrichment Analysis
To determine which genes sets are significantly 
enriched in the Ago2-IP in comparison to the total fraction 
we performed Gene Set Enrichment Analysis using The 
Molecular Signatures Database (GSEA; http://www.broad.
mit.edu/gsea) [36]. If more than one probe was assigned 
for a certain gene, we selected the probe with the highest 
IP fold enrichment.
Transfection and luciferase assay
Luciferase assays were performed using the 
Promega Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI) as described previously [37]. 
Briefly, two million ST486 cells were transfected with 
4µg of each psiCHECK2 construct and co-transfected with 
100nM miR-155 precursor or negative control #1 (both 
Ambion) using an Amaxa nucleofector device, program 
A23 (Amaxa, Gaithersburg, MD). Transfections were 
performed in triplicate and cell lysates were made 24h 
after transfection. Renilla to Firefly (RL/FL) luciferase 
ratios were calculated and compared to negative control 
(set at 100%). Significance was calculated using the t-test.
Western Blot
Western blot for DET1 was performed as previously 
described [38]. Immunoblots were incubated with 
mouse anti-DET1 antibody (clone 3G5, Genentech, San 
Francisco, CA) at a concentration of 1 µg/ml in 5% milk 
in Tris-buffered saline with Tween-20 (TBST) overnight at 
4ºC. Mouse anti-GAPDH antibody (clone 0411, 1:20,000, 
Santa Cruz, CA, USA) was used as a control. Western Blot 
for NIAM was performed using a rabbit polyclonal anti-
NIAM antibody (18951-1-AP, Proteintech, Chicago, IL, 
USA) diluted 1:500 in 5% milk in TBST overnight at 4ºC.
GFP competition assay
GFP expression was measured on a FACS Calibur 
flow cytometer (BD PharMingen) at day 3 or 4 post-
transduction and monitored for three weeks tri-weekly. 
The percentage of GFP+ cells was analyzed using 
FlowJo software (version 7.6, Treestar, Ashland, OR); the 
value at day 3 or 4 was set to 1 and the fold difference 
per measurement was calculated. To determine whether 
cells with increased miR-155 or decreased TBRG1 levels 
grow significantly different from cells transduced with 
control vectors, we performed mixed model analysis on 
the relative percentages with the interaction between 
transduced cell type and day of measurement as fixed 
effects and day of measurements and the biological 
replicate measurements as within-subject variables in 
SPSS (version 22). Since the relative percentages were 
1 on day 3 or 4 by definition, we analyzed the relative 
percentage -1 and did not include the intercept and the 




Sections of BL, CLL and DLBCL cases were 
cut (3µm) and staining was performed using a rabbit 
polyclonal anti-NIAM antibody (18951-1-AP, 1:25, 
Proteintech) in combination with microwave-citrate buffer 
(pH 6.0) antigen retrieval. Staining was visualized using 
a peroxidase coupled goat anti-rabbit secondary antibody 
(1:100), a peroxidase-coupled rabbit anti-goat tertiary 
antibody (1:100, both DAKO, Glostrup, Denmark), and 
3,3-diaminobenzidine tetrachloride.
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